RxDoctor Payments Data

Aasim Mohammed, MD

Pulmonary Disease · Burlington, WINPI 1326477233

Payments from drug & device makers

$3,742in general payments, 2019–2025

Across 103 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$989
  • Boehringer Ingelheim$474
  • Sanofi$259
  • Pulmonx Corporation$237
  • United Therapeutics Corporation$143
  • plus $550 from 9 others

What the payments were for

  • Food & beverage$3,726100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,742 in reported general payments places this provider in the 70th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$141,564
Medicare patients
597
Services billed
1,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter453$377,533
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$59,580
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr57$32,140
Breo ElliptaFluticasone/Vilanterol40$17,051
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$11,335
Incruse ElliptaUmeclidinium Bromide15$4,982
Albuterol Sulfate HfaAlbuterol Sulfate171$4,841
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$4,787
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,037
Roflumilast25$1,045
Azelastine Hcl48$972
Montelukast Sodium57$630
Gabapentin60$557
Ropinirole Hcl24$499
Fluticasone Propionate20$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$989$431,706565 claims
AstraZenecaBreztri Aerosphere$1,090$59,58065 claims
Boehringer IngelheimStiolto Respimat$474$11,33520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 247 pulmonary disease providers in Wisconsin.

Other pulmonary disease in Burlington

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →